181 related articles for article (PubMed ID: 26360803)
1. Somatic BRAF c.1799T>A p.V600E Mosaicism syndrome characterized by a linear syringocystadenoma papilliferum, anaplastic astrocytoma, and ocular abnormalities.
Watanabe Y; Shido K; Niihori T; Niizuma H; Katata Y; Iizuka C; Oba D; Moriya K; Saito-Nanjo Y; Onuma M; Rikiishi T; Sasahara Y; Watanabe M; Aiba S; Saito R; Sonoda Y; Tominaga T; Aoki Y; Kure S
Am J Med Genet A; 2016 Jan; 170A(1):189-94. PubMed ID: 26360803
[TBL] [Abstract][Full Text] [Related]
2. Pilomyxoid astrocytoma treated successfully with vemurafenib.
Skrypek M; Foreman N; Guillaume D; Moertel C
Pediatr Blood Cancer; 2014 Nov; 61(11):2099-100. PubMed ID: 24821190
[TBL] [Abstract][Full Text] [Related]
3. Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib.
van Tilburg CM; Selt F; Sahm F; Bächli H; Pfister SM; Witt O; Milde T
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29230924
[TBL] [Abstract][Full Text] [Related]
4. Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy.
Lee EQ; Ruland S; LeBoeuf NR; Wen PY; Santagata S
J Clin Oncol; 2016 Apr; 34(10):e87-9. PubMed ID: 25092772
[No Abstract] [Full Text] [Related]
5. Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series.
Chamberlain MC
J Neurooncol; 2013 Sep; 114(2):237-40. PubMed ID: 23756728
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetics of Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E-Mutant Astrocytomas.
Wang H; Long-Boyle J; Winger BA; Nicolaides T; Mueller S; Prados M; Ivaturi V
J Clin Pharmacol; 2020 Sep; 60(9):1209-1219. PubMed ID: 32476174
[TBL] [Abstract][Full Text] [Related]
7. Schimmelpenning-Feuerstein-Mims syndrome induced by HRAS Gly12Ser somatic mosaic mutation: Case report and literature review.
Ono H; Yamaguchi R; Arai M; Togi S; Ura H; Niida Y; Shimizu A
J Dermatol; 2023 Sep; 50(9):1213-1215. PubMed ID: 37170693
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
Thompson EM; Landi D; Ashley D; Keir ST; Bigner D
J Neurooncol; 2018 Nov; 140(2):261-268. PubMed ID: 30120661
[TBL] [Abstract][Full Text] [Related]
9. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
[TBL] [Abstract][Full Text] [Related]
10. BRAF and KRAS mutations in tubular apocrine adenoma and papillary eccrine adenoma of the skin.
Liau JY; Tsai JH; Huang WC; Lan J; Hong JB; Yuan CT
Hum Pathol; 2018 Mar; 73():59-65. PubMed ID: 29241739
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy for BRAFV600E malignant astrocytoma.
Nicolaides TP; Li H; Solomon DA; Hariono S; Hashizume R; Barkovich K; Baker SJ; Paugh BS; Jones C; Forshew T; Hindley GF; Hodgson JG; Kim JS; Rowitch DH; Weiss WA; Waldman TA; James CD
Clin Cancer Res; 2011 Dec; 17(24):7595-604. PubMed ID: 22038996
[TBL] [Abstract][Full Text] [Related]
12. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.
Robinson SD; O'Shaughnessy JA; Cowey CL; Konduri K
Lung Cancer; 2014 Aug; 85(2):326-30. PubMed ID: 24888229
[TBL] [Abstract][Full Text] [Related]
13. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
14. Giant syringocystadenocarcinoma papilliferum with conjunctival recurrence: Possible Schimmelpenning syndrome with postzygotic G13R HRAS and K601N BRAF signature.
Dupont A; Vergara R; Pacaud A; Dequidt L; Dutriaux C; Saunier V; Caumont C; Jullie ML; Taïeb A; Morice-Picard F; Dousset L
J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):e1420-e1422. PubMed ID: 37458522
[No Abstract] [Full Text] [Related]
15. Somatic V600E BRAF Mutation in Linear and Sporadic Syringocystadenoma Papilliferum.
Levinsohn JL; Sugarman JL; Bilguvar K; McNiff JM; Choate KA; The Yale Center For Mendelian Genomics
J Invest Dermatol; 2015 Oct; 135(10):2536-2538. PubMed ID: 25950823
[No Abstract] [Full Text] [Related]
16. Activating mutations in the RAS/mitogen-activated protein kinase signaling pathway in sporadic trichoblastoma and syringocystadenoma papilliferum.
Shen AS; Peterhof E; Kind P; Rütten A; Zelger B; Landthaler M; Berneburg M; Hafner C; Groesser L
Hum Pathol; 2015 Feb; 46(2):272-6. PubMed ID: 25532942
[TBL] [Abstract][Full Text] [Related]
17. Vemurafenib treatment of BRAF V600E-mutated malignant peripheral nerve sheath tumor.
Kaplan HG
J Natl Compr Canc Netw; 2013 Dec; 11(12):1466-70. PubMed ID: 24335681
[TBL] [Abstract][Full Text] [Related]
18. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.
Kopetz S; Desai J; Chan E; Hecht JR; O'Dwyer PJ; Maru D; Morris V; Janku F; Dasari A; Chung W; Issa JP; Gibbs P; James B; Powis G; Nolop KB; Bhattacharya S; Saltz L
J Clin Oncol; 2015 Dec; 33(34):4032-8. PubMed ID: 26460303
[TBL] [Abstract][Full Text] [Related]
19. [Cystic tubulopapillary adenoma with apocrine differentiation and BRAF V600E mutation. A case report and review of the literature].
Moreno Ontalba A; Gómez Durán Á; Ruiz Cabezas L; Cidoncha Pérez E; Díaz Delgado M; Rubio Fernández A
Rev Esp Patol; 2022 Sep; 55 Suppl 1():S64-S68. PubMed ID: 36075666
[TBL] [Abstract][Full Text] [Related]
20. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Brose MS; Cabanillas ME; Cohen EE; Wirth LJ; Riehl T; Yue H; Sherman SI; Sherman EJ
Lancet Oncol; 2016 Sep; 17(9):1272-82. PubMed ID: 27460442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
